Calidi Biotherapeutics Inc Ordinary Shares - Class A CLDI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLDI is a good fit for your portfolio.
News
-
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
-
Sidoti Events, LLC's Virtual May Micro-Cap Conference
-
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
-
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
-
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
-
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
-
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
-
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
Trading Information
- Previous Close Price
- $0.22
- Day Range
- $0.21–0.24
- 52-Week Range
- $0.14–13.79
- Bid/Ask
- $0.21 / $0.24
- Market Cap
- $11.06 Mil
- Volume/Avg
- 278,958 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 41
- Website
- https://www.calidibio.com
Valuation
|
Metric
|
CLDI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CLDI
|
|---|---|
Quick Ratio | 0.32 |
Current Ratio | 0.42 |
Interest Coverage | −26.32 |
Quick Ratio
CLDI
Profitability
|
Metric
|
CLDI
|
|---|---|
Return on Assets (Normalized) | −240.75% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CLDI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nyfvfmmvj | Xwrw | $585.2 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mgwrskhp | Cczmbt | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hggfnbs | Lwmvv | $107.6 Bil | |
MRNA
| Moderna Inc | Kmttwwfww | Pqzqb | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Frkgxrxvx | Cwtzg | $22.3 Bil | |
ARGX
| argenx SE ADR | Hsdyqzfh | Vwwhm | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tfyvmvpdv | Ggfgqp | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bgvxjmcv | Gnvzjp | $15.1 Bil | |
INCY
| Incyte Corp | Pkhktybnw | Szydfcz | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dgcgvlndjw | Wknwp | $12.7 Bil |